Chordate Medical has received preliminary approval from Nasdaq regarding a list change to Nasdaq First North Growth Market

31 January, 2022

Chordate Medical (publ) ("Chordate" or "the company") has today received preliminary approval from Nasdaq Stockholm AB ("Nasdaq") regarding admission to trading of its shares on the Nasdaq First North Growth Market. Provided that Chordate formally applies for approval, fulfills the prevailing conditions and is finally approved by Nasdaq, it is deemed that the list change can be carried out with first trading day on Nasdaq being on February 15th, 2022. NGM SME, where the company's shares are listed, approved the Company's application for delisting on January 28th, 2022, with a preliminary last trading day on February 14th, 2022, provided that trading in the Company's shares can be admitted on Nasdaq First North Growth Market the following trading day.

As previously communicated, The Board believes that a change of trading venue for the company's shares to Nasdaq First North Growth Market will increase the knowledge of the company both in Sweden and internationally, making it easier for industrial investors to become shareholders, and have a positive impact on the company's relationships with partners and potential customers. Overall, a change of trading venue is considered to be positive for Chordate's development and completion of the stated exit strategy.

Provided that Chordate receives final approval from Nasdaq, the company's shares will continue to be traded under the short name CMH with the current ISIN code SE0009495559. Shareholders in Chordate will not have to take any action in the event of a change of trading venue.

Västra Hamnen Corporate Finance AB is Chordate's advisor regarding the planned list change and Certified Adviser. Wistrand Advokatbyrå AB is Chordate's legal advisor.

This disclosure was submitted for publication, through the contact person below, on January 31st, 2022, at 15:30 am CET.

For more information, please contact:
Anders Weilandt, CEO
Cell: +46 733-874277

Fler Nyheter

Press releases

If you want to read our press releases, there are available in the Investor Relations section or by clicking the link below.

Press releases

For questions about Chordate's share price or other investment-related topics, please see if the answer is here.

For questions about the medical effects of the K.O.S treatment, please see if the answer is here.

To get in touch with Chordate regarding other questions, use the adjecent form. We do our best to respond as quickly as possible.

Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company's share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.


Contact us

The information is handled according to our  privacy policy.